Literature DB >> 28681347

New concepts on the clinical course and stratification of compensated and decompensated cirrhosis.

Gennaro D'Amico1, Alberto Morabito2, Mario D'Amico3, Linda Pasta4, Giuseppe Malizia4, Paola Rebora5, Maria Grazia Valsecchi5.   

Abstract

The clinical course of cirrhosis has been typically described by a compensated and a decompensated state based on the absence or, respectively, the presence of any of bleeding, ascites, encephalopathy or jaundice. More recently, it has been recognized that increasing portal hypertension and several major clinical events are followed by a marked worsening in prognosis, and disease states have been proposed accordingly in a multistate model. The development of multistate models implies the assessment of the probabilities of more than one possible outcome from each disease state. This requires the use of competing risks analysis which investigates the risk of several competing outcomes. In such a situation, the Kaplan-Meier risk estimates and the Cox regression may be not appropriate. Clinical states of cirrhosis presently considered as suitable for a comprehensive multistate model include: in compensated cirrhosis, early (mild) portal hypertension with hepatic venous pressure gradient (HVPG) >5 and <10 mmHg, clinically significant portal hypertension (HVPG ≥ 10 mmHg) without gastro-esophageal varices (GEV), and GEV; in decompensated cirrhosis, a first variceal bleeding without other decompensating events, any first non-bleeding decompensation and any second decompensating event; and in a late decompensation state, refractory ascites, sepsis, renal failure, recurrent encephalopathy, profound jaundice, acute on chronic liver failure, all predicting a very short survival. In this review, we illustrate how competing risks analysis and multistate models may be applied to cirrhosis.

Entities:  

Keywords:  Cirrhosis; Clinical states; Competing risks; Multistate model; Portal hypertension; Prognosis; Risk stratification

Mesh:

Year:  2017        PMID: 28681347     DOI: 10.1007/s12072-017-9808-z

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  18 in total

1.  Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data.

Authors:  Francesco Salerno; Calogero Cammà; Marco Enea; Martin Rössle; Florence Wong
Journal:  Gastroenterology       Date:  2007-06-20       Impact factor: 22.682

2.  Tutorial in biostatistics: competing risks and multi-state models.

Authors:  H Putter; M Fiocco; R B Geskus
Journal:  Stat Med       Date:  2007-05-20       Impact factor: 2.373

3.  The natural history of compensated HCV-related cirrhosis: a prospective long-term study.

Authors:  Eduardo Vilar Gomez; Yoan Sanchez Rodriguez; Luis Calzadilla Bertot; Ana Torres Gonzalez; Yadina Martinez Perez; Enrique Arus Soler; Ali Yasells Garcia; Luis Perez Blanco
Journal:  J Hepatol       Date:  2012-10-27       Impact factor: 25.083

4.  Transection of the oesophagus for bleeding oesophageal varices.

Authors:  R N Pugh; I M Murray-Lyon; J L Dawson; M C Pietroni; R Williams
Journal:  Br J Surg       Date:  1973-08       Impact factor: 6.939

5.  Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension.

Authors:  Càndid Villanueva; Agustín Albillos; Joan Genescà; Juan G Abraldes; Jose L Calleja; Carles Aracil; Rafael Bañares; Rosa Morillas; María Poca; Beatriz Peñas; Salvador Augustin; Joan Carles Garcia-Pagan; Oana Pavel; Jaume Bosch
Journal:  Hepatology       Date:  2015-11-26       Impact factor: 17.425

6.  Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis.

Authors:  Vasiliki Arvaniti; Gennaro D'Amico; Giuseppe Fede; Pinelopi Manousou; Emmanuel Tsochatzis; Maria Pleguezuelo; Andrew Kenneth Burroughs
Journal:  Gastroenterology       Date:  2010-06-14       Impact factor: 22.682

Review 7.  Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis.

Authors:  Mauro Bernardi; Richard Moreau; Paolo Angeli; Bernd Schnabl; Vicente Arroyo
Journal:  J Hepatol       Date:  2015-07-17       Impact factor: 25.083

8.  Natural history of patients hospitalized for management of cirrhotic ascites.

Authors:  Ramon Planas; Silvia Montoliu; Belen Ballesté; Monica Rivera; Mireia Miquel; Helena Masnou; Jose Antonio Galeras; María D Giménez; Justiniano Santos; Isabel Cirera; Rosa María Morillas; Susanna Coll; Ricard Solà
Journal:  Clin Gastroenterol Hepatol       Date:  2006-11       Impact factor: 11.382

Review 9.  Renal failure and cirrhosis: a systematic review of mortality and prognosis.

Authors:  Giuseppe Fede; Gennaro D'Amico; Vasiliki Arvaniti; Emmanuel Tsochatzis; Giacomo Germani; Dimosthenis Georgiadis; Alberto Morabito; Andrew Kenneth Burroughs
Journal:  J Hepatol       Date:  2011-12-13       Impact factor: 25.083

10.  Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study.

Authors:  Savino Bruno; Massimo Zuin; Andrea Crosignani; Sonia Rossi; Felice Zadra; Luigi Roffi; Mauro Borzio; Alessandro Redaelli; Alberto Chiesa; Enrico Maria Silini; Piero Luigi Almasio; Patrick Maisonneuve
Journal:  Am J Gastroenterol       Date:  2009-04-07       Impact factor: 10.864

View more
  21 in total

1.  Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Authors:  Roberto Minutolo; Alessio Aghemo; Antonio Chirianni; Fabrizio Fabrizi; Loreto Gesualdo; Edoardo G Giannini; Paolo Maggi; Vincenzo Montinaro; Ernesto Paoletti; Marcello Persico; Francesco Perticone; Salvatore Petta; Massimo Puoti; Giovanni Raimondo; Maria Rendina; Anna Linda Zignego
Journal:  Infection       Date:  2018-09-25       Impact factor: 3.553

2.  Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Authors:  Roberto Minutolo; Alessio Aghemo; Antonio Chirianni; Fabrizio Fabrizi; Loreto Gesualdo; Edoardo G Giannini; Paolo Maggi; Vincenzo Montinaro; Ernesto Paoletti; Marcello Persico; Francesco Perticone; Salvatore Petta; Massimo Puoti; Giovanni Raimondo; Maria Rendina; Anna Linda Zignego
Journal:  J Nephrol       Date:  2018-09-25       Impact factor: 3.902

3.  Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).

Authors:  Roberto Minutolo; Alessio Aghemo; Antonio Chirianni; Fabrizio Fabrizi; Loreto Gesualdo; Edoardo G Giannini; Paolo Maggi; Vincenzo Montinaro; Ernesto Paoletti; Marcello Persico; Francesco Perticone; Salvatore Petta; Massimo Puoti; Giovanni Raimondo; Maria Rendina; Anna Linda Zignego
Journal:  Intern Emerg Med       Date:  2018-09-25       Impact factor: 3.397

Review 4.  Hedgehog signalling in liver pathophysiology.

Authors:  Mariana Verdelho Machado; Anna Mae Diehl
Journal:  J Hepatol       Date:  2017-10-26       Impact factor: 25.083

Review 5.  Indian National Association for the Study of the Liver Consensus Statement on Acute Liver Failure (Part 1): Epidemiology, Pathogenesis, Presentation and Prognosis.

Authors:  Anil C Anand; Bhaskar Nandi; Subrat K Acharya; Anil Arora; Sethu Babu; Yogesh Batra; Yogesh K Chawla; Abhijit Chowdhury; Ashok Chaoudhuri; Eapen C Eapen; Harshad Devarbhavi; RadhaKrishan Dhiman; Siddhartha Datta Gupta; Ajay Duseja; Dinesh Jothimani; Dharmesh Kapoor; Premashish Kar; Mohamad S Khuroo; Ashish Kumar; Kaushal Madan; Bipadabhanjan Mallick; Rakhi Maiwall; Neelam Mohan; Aabha Nagral; Preetam Nath; Sarat C Panigrahi; Ankush Pawar; Cyriac A Philips; Dibyalochan Prahraj; Pankaj Puri; Amit Rastogi; Vivek A Saraswat; Sanjiv Saigal; Akash Shukla; Shivaram P Singh; Thomas Verghese; Manav Wadhawan
Journal:  J Clin Exp Hepatol       Date:  2020-04-28

6.  Predicting outcome in liver patients admitted to intensive care: A dual-centre non-specialist hospital external validation of the Liver injury and Failure evaluation score.

Authors:  Eleanor de Sausmarez; Paul Crowest; Steve Fry; Luke Hodgson
Journal:  J Intensive Care Soc       Date:  2020-05-08

7.  Plasma levels of methylated septin 9 are capable of detecting hepatocellular carcinoma and hepatic cirrhosis.

Authors:  Na He; Gong Feng; Chunyan Zhang; Fangxiong Wu; Ting Zhang; Yongqin Yang
Journal:  Mol Med Rep       Date:  2020-07-23       Impact factor: 2.952

Review 8.  Genetic modification by overexpression of target gene in mesenchymal stromal cell for treating liver diseases.

Authors:  Chenxia Hu; Lingfei Zhao; Lanjuan Li
Journal:  J Mol Med (Berl)       Date:  2021-01-02       Impact factor: 4.599

9.  Efficacy and Safety of Emricasan in Liver Cirrhosis and/or Fibrosis.

Authors:  Li-Ya Mu; Shu-Qin Li; Li-Xin Tang; Rui Li
Journal:  Clinics (Sao Paulo)       Date:  2021-06-14       Impact factor: 2.365

Review 10.  Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives.

Authors:  Natascha Roehlen; Emilie Crouchet; Thomas F Baumert
Journal:  Cells       Date:  2020-04-03       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.